Opinion of the Transparency Council – axitinib
At its meeting on 26 August 2024, the Transparency Council adopted opinion No. 138/2024 on the transfer of the active substance axitinib from the drug program: B.10 “Treatment of patients with renal cell carcinoma (ICD-10: C64)” to the catalog of reimbursable drugs in chemotherapy